김동욱 교수

논문

• Brain-Decellularized ECM-Based 3D Myeloid Sarcoma Platform: Mimicking Adaptive Phenotypic Alterations in the Brain. Advanced Healthcare Materials 2024
  Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia. Molecular Cancer 2023
  Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment free remission attempt in chronic myelogenous leukemia. Neoplasia 2022
  Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea. Blood Research 2022
  Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia. Cancer Medicine 2022
  Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia. Leukemia Research 2022
  Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 2021
  Change of right ventricular systolic pressure can indicate dasatinib-induced pulmonary arterial hypertension in chronic myeloid leukemia. Cancer Medicine 2021
  Prognosis Score System to Predict Survival for COVID-19 Cases: a Korean Nationwide Cohort Study. Journal of Medical Internet Research 2021
  Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers (Basel) 2021
  Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia. Journal of Clinical Pharmacy and Therapeutics 2020
  Successful Prevention and Screening Strategies for COVID-19: Focused on Patients With Hematologic Diseases. British Journal of Haematology 2020
  Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option. Frontiers in Oncology 2020
  Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). British Journal of Haematology 2020
  Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia. International Journal of Hematology 2020
  Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine 2019
  GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia. Autophagy 2019
  Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2019
  Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia. Leukemia Research 2019
  Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia 2018
  BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors. Cancer Medicine 2018
  Outcomes of switching to dasatinib after imatinib-related low grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Annals of Hematology 2018
  Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Medicine 2018
  Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clinical Cancer Research 2017
  Cobll1: A new player in CML. Oncotarget 2017
  Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia 2017